{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:13:42Z","timestamp":1784859222291,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":3021,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.bbmt.2006.08.037","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T07:59:01Z","timestamp":1168502341000},"page":"56-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"title":["Pharmacokinetics of Once-Daily IV Busulfan as Part of Pretransplantation Preparative Regimens: A Comparison with an Every 6-Hour Dosing Schedule"],"prefix":"10.1016","volume":"13","author":[{"given":"Timothy","family":"Madden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Thapar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonja","family":"Roberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Couriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borje S.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2006.08.037_bib1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2006.08.037_bib2","first-page":"711","article-title":"Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue","volume":"68","author":"Lu","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.bbmt.2006.08.037_bib3","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.08.037_bib4","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"8","article-title":"Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination","author":"Benet","year":"1985"},{"key":"10.1016\/j.bbmt.2006.08.037_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 4","key":"10.1016\/j.bbmt.2006.08.037_bib6","first-page":"18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2006.08.037_bib7","first-page":"31","article-title":"Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib8","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.08.037_bib10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.08.037_bib11","first-page":"759","article-title":"Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?","volume":"14","author":"Schuler","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","article-title":"Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematological malignancies","volume":"26","author":"Tran","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002800050404","article-title":"Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy","volume":"37","author":"Bhagwatwar","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2006.08.037_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/bbmt.2002.v8.pm12374453","article-title":"Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation","volume":"8","author":"Fernandez","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbmt.2004.05.010","article-title":"Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies","volume":"10","author":"Williams","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.08.037_bib20","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":"Busulfan bioavailability","volume":"84","author":"Hassan","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.08.037_bib21","first-page":"2083","article-title":"Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation","volume":"16","author":"Buggia","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bbmt.2006.08.037_bib22","first-page":"171","article-title":"Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis","volume":"18","author":"Styler","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.bmt.1703896","article-title":"The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation","volume":"31","author":"Nilsson","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00686213","article-title":"Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics","volume":"33","author":"Hassan","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2006.08.037_bib25","series-title":"ADAPT II User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D\u2019Argenio","year":"1997"},{"key":"10.1016\/j.bbmt.2006.08.037_bib26","series-title":"A Clinician\u2019s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics","first-page":"189","article-title":"Busulfan","author":"Hassan","year":"1997"},{"key":"10.1016\/j.bbmt.2006.08.037_bib27","first-page":"722","article-title":"Intravenous versus oral busulfan\u2014perhaps not as different as suggested","volume":"11","author":"Slattery","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2006.08.037_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1200\/JCO.1996.14.5.1484","article-title":"Conditioning regimen-related disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients","volume":"14","author":"Slattery","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2006.08.037_bib29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/(SICI)1520-636X(1999)11:7<569::AID-CHIR9>3.0.CO;2-R","article-title":"Enantioselective induction of cyclophosphamide metabolism by phenytoin","volume":"11","author":"Williams","year":"1999","journal-title":"Chirality"},{"key":"10.1016\/j.bbmt.2006.08.037_bib30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0090-9556(24)14957-4","article-title":"Up-regulation of glutathione-S-transferase activity in enterocytes of young children","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.bbmt.2006.08.037_bib31","first-page":"6203","article-title":"Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study","volume":"50","author":"Vassal","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2006.08.037_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00686397","article-title":"In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient","volume":"30","author":"Hassan","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2006.08.037_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V104.11.97.97","article-title":"IV busulfan (Bu) with fludarabine (Flu) or cyclophosphamide (Cy)\u2014comparing ablative conditioning regimens for allogeneic transplantation in AML\/MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2006.08.037_bib34","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft vs. host disease; defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106006033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879106006033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:27:43Z","timestamp":1761056863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879106006033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S1083879106006033"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.08.037","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of Once-Daily IV Busulfan as Part of Pretransplantation Preparative Regimens: A Comparison with an Every 6-Hour Dosing Schedule","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2006.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}